Abstract: The present invention relates to an assay for detecting Tumstatin, and its use in evaluating lung cancers, such as non-small cell lung cancer (NSCLC), chronic kidney disease (CKD), such as CKD resulting from diabetes, lupus nephritis (LN) and systemic lupus erythematosus (SLE).

Abstract: The present invention relates to humanised calcitonin mimetics and their use in treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease, alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poor regulation of food intake.

Abstract: An antibody specifically reactive with an N-terminus neo-epitope of collagen type X alpha 1 comprised in the amino acid sequence H2N-GIATKGLNGP, and its use in an immunoassay for evaluating a disease associated with collagen type X alpha 1, such as osteoarthritis.

Abstract: An antibody specifically reactive with an epitope of collagen type X alpha 1 comprised in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1), and a method of immunoassay for detecting in a biological sample an epitope in the NC1 domain C-terminal amino acid sequence SFSGFLVAPM-COOH (SEQ ID NO: 1) of collagen type X alpha 1, by contacting the biological sample with the antibody, and determining the amount of binding of the antibody.

Abstract: The present invention relates to an antibody, wherein the antibody specifically binds to the N-terminus of Lysyl Oxidase-Like 2 (LOXL2), and its use in a method of immunoassay for detecting or quantitating LOXL2 in a sample. The method may be used to evaluate LOXL2-associated diseases, and may also be used to evaluate the efficacy of anti-LOXL2 therapeutics.

Abstract: The present invention relates to an antibody, wherein the antibody is specifically reactive with short isoform collagen type XVIII, but does not react with intermediate isoform collagen type XVIII or with long isoform collagen type XVIII. The invention also relates to the use of the antibody in a method of immunoassay for detecting or quantitating short isoform collagen type XVIII, wherein the method may be used to evaluate haemophilic disease.

Abstract: Provided herein are methods of selecting subjects having cancer for combination therapy that includes administering an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme. Combination therapies can include, in addition to the anti-hyaluronan agent, a tumor-targeted taxane and, optionally, a chemotherapeutic agent such as a nucleoside analog. Combinations for performing the methods are provided, as are uses of the combinations for selecting subjects for treatment. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: Provided is a method of diagnosis or of quantitation of cancer. In the method a patient biofluid sample is obtained, an immunoassay is conducted to measure fragments of Nidogen-1 that have an N- or C-terminal neo-epitope formed by cleavage of Nidogen-1 by Cathepsin-S, where the fragments are naturally present in the sample, and associating an elevation of the measure in the patient above a normal level is associated with the presence or extent of cancer.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: A method of immunoassay for detecting in a biological sample a fragment of collagen type VII alpha 1 comprising an N- or C-terminal neo-epitope, the method comprising contacting the biological sample comprising the fragment of collagen type VII alpha 1 comprising the N- or C-terminal neo-epitope with an antibody of the invention, and determining the amount of binding of the antibody

Abstract: Calcitonin mimetic peptides having an amino acid sequence in accordance with SEQ ID NO:8 or SEQ ID NO:53, each of which may be carboxylated at its N-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its C-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by ?-aminosuberic acid (Asu) are useful for methods of treating diabetes (Type I and/or Type II), obesity, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated food intake.

Abstract: Provided is a method of bioassay for the quantification of N- or C-terminal neo-epitope biomarkers formed by cleavage of a CRP, ApoE, lumican, versican, perlecan, decorin, biglycan or elastin by a proteinase. The method includes contacting a biofluid sample with an antibody reactive with the neo-epitope biomarker and determining the level of binding of the antibody to the biomarker in the sample. The assay is predictive of risk of cardiovascular disease events.

Abstract: Calcitonin mimetic peptides having an amino acid sequence in accordance with SEQ ID NO:8 or SEQ ID NO:53, each of which may be carboxylated at its N-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its C-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by ?-aminosuberic acid (Asu) are useful as medicaments for treating diabetes (Type I and/or Type II), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated of food intake.

Abstract: Calcitonin analogues as a medicament for producing a decrease in liver triglycerides or for reducing fat accumulation in the liver of a subject are provided.

Abstract: Provided is a method of bioassay for the quantification of peptide fragments elevated in lung diseases such as COPD, SCC, or IPF. The peptide fragments comprise a neo-epitope formed at a cleavage site by cleavage in vivo of elastin by a proteinase. In the method a sample is contacted with an antibody having specific binding affinity for the neo-epitope amino acid sequence and determining the level of binding is determined where the antibody binds one of the following terminal sequences: . . . FGPGVV, . . . VPGLGV or IKAPKL . . . . Also provided are antibodies and immunoassay kits for use in such methods.

Abstract: A method of bioassay for the quantification of peptide fragments comprising a neo-epitope formed by cleavage of mimecan, a protein of an atherosclerotic plaque, by a proteinase is provided. In the method a sample, such as urine or serum, is contacted with an antibody reactive with the neo-epitope and the level of binding of the antibody to peptide fragments in the sample is determined. The assay is predictive of risk of cardiovascular disease events.

Abstract: A method of bioassay for the quantification of biomarkers useful in the diagnosis of fibrosis disease and prognosis of its development, including biomarkers indicative of the risk of developing fibrosis after a chronic injury is provided. In particular, according to the present invention, biomarkers relating to degradation fragments of Collagen type I, III, IV, V, and VI, elastin, C-reactive protein, and proteoglycans including Biglycan, Decorin, Versican, and Perlecan are found to be useful.

Abstract: Provided herein is a sandwich immunoassay for detecting cross-linked PIIINP that has at least two strands of PIIINP joined together by inter-strand cross-linking each having a C-terminal neo-epitope of PIIINP that is generated by N-protease cleavage of intact type III procollagen. A biological sample having the cross-linked PIIINP is contacted with a first surface-bound monoclonal antibody and then by a second monoclonal antibody, both specifically reactive with a neoepitope in the C-terminal sequence of PIIINP, and then binding of the second monoclonal antibody is determined. Also provided is a method for evaluating the efficacy of an antagonist drug targeting lysyl oxidases via the immunoassay and a kit containing a solid support binding the first monoclonal antibody and containing the second monoclonal antibody.

Abstract: Provided herein is a method of bioassay for the quantification of peptide fragments relevant to neurodegenerative conditions. The method comprises cleaving a Tau protein by a secretase, such as ADAM10, to form a neo-epitope. The method comprises contacting a blood derived sample with an antibody specific for the neo-epitope and determining the level of binding of the antibody to peptide fragments comprising the neo-epitope in the sample. Neo-epitope containing peptide levels are found to be inversely correlated to cognitive function.